- Home
- / Nykode Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Nykode Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
KR4.8
2024-10-29
Market Capitalization
KR1.6 B
2024-10-29
CreditSafe Score
?
Score changed on Jun 07, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 215.7M | 34.0M | 7.2M | 12.9M | 8.7M | ||
| Cost of goods sold | 2.4M | 2.7M | 2.5M | 1.3M | |||
| Gross profit | 1.4M | 215.7M | 35.8M | 6.7M | 10.6M | 6.6M | (801.0K) |
| Gross profit margin, % | 100.0% | 105.3% | 93.1% | 82.2% | 76.3% | ||
| Operating expense total | 15.2M | 37.1M | 45.8M | 58.0M | 66.6M | 52.7M | 23.7M |
| Depreciation and amortization | 160.0K | 303.0K | 735.0K | 1.8M | 2.1M | 2.3M | 2.0M |
| EBITDA | (13.8M) | 178.6M | (10.0M) | (51.3M) | (56.0M) | (46.1M) | (24.5M) |
| EBITDA margin, % | 82.8% | -29.6% | -716.3% | -433.7% | -530.9% | ||
| EBIT | (13.9M) | 178.3M | (10.8M) | (53.2M) | (58.1M) | (48.3M) | (26.6M) |
| EBIT margin, % | 82.6% | -31.7% | -741.6% | -450.2% | -556.9% | ||
| Interest income | 387.0K | 198.0K | 270.0K | 3.7M | 8.9M | 7.0M | 3.6M |
| Interest expense | 34.0K | 264.0K | 129.0K | 378.0K | 224.0K | 188.0K | 124.0K |
| Pre tax profit | (13.7M) | 180.9M | (11.1M) | (51.0M) | (44.1M) | (45.5M) | (17.7M) |
| Income tax expense | 31.1M | (1.7M) | (8.2M) | (8.9M) | (6.7M) | (5.5M) | |
| Net Income | (13.7M) | 149.8M | (9.4M) | (42.7M) | (35.2M) | (38.8M) | (12.2M) |